Insights

Dr Rubin, from the University of Chicago, discusses how using a treat to target approach can enhance patient quality of life, achieve tight control of inflammatory bowel disease, and ensure optimal outcomes.

Dr Charabaty, from Johns Hopkins University School of Medicine, reviews her presentation from the Advances in Inflammatory Bowel Diseases regional meeting in Chicago on the key steps for managing the patient with acute severe ulcerative...

Dr Regueiro, from Cleveland Clinic and chair of the AIBD regional meeting in Chicago, provides an overview of the faculty and topics that will be featured.

In this episode of IBD Drive Time, hosts Raymond Cross, MD, and Millie Long, MD, talk to Dr Sara Horst of Vanderbilt University about the newly approved IL-23 inhibitor, risankizumab, and its benefit in treating inflammatory bowel disease.

In this episode of IBD Drive Time, your hosts Drs Ray Cross and Millie Long discuss the best abstracts from Digestive Disease Week 2022 with Dr Dave Hudesman.

Dr Horst, from Vanderbilt University Medical Center, reviews the key points of her presentation from Digestive Disease Week 2022 on treatment options for patients with ulcerative colitis for whom multiple biologic treatments have failed.

In this episode of IBD Drive Time, guest Meena Bewtra, MD, from the University of Pennsylvania, joins hosts Raymond Cross, MD, from the University of Maryland and Millie Long, MD, from the University of North Carolina, to discuss top...

Dr Higgins gives a recap of his poster presentation at Digestive Disease Week 2022 on evaluating the impact of baseline ulcerative colitis characteristics on clinical outcomes following treatment with upadacitinib.